Clarivate Epidemiology’s coverage of achromatopsia (ACHM) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of ACHM for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s ACHM forecast will answer the following questions:
- Of all people with ACHM, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ACHM over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts four ACHM patient populations, as follows:
- Diagnosed prevalent cases of ACHM.
- Diagnosed prevalent cases of ACHM by CNGA3+ mutation.
- Diagnosed prevalent cases of ACHM by CNGB3+ mutation.
- Diagnosed prevalent cases of ACHM by other/unknown status.
Note: Coverage may vary by country.
Prashant Kumar
Prashant Kumar, M.P.H., Epidemiologist. Prior to joining the company, he coordinated various public health projects focused on tuberculosis, COVID, and malnutrition. He also has experience working in the health insurance domain in India, where he was involved in claims data analytics and stakeholder management. He holds an M.P.H specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.